FT516 in Subjects With Advanced Hematologic Malignancies
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia
(AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The
study will consist of a dose-escalation stage and an expansion stage where participants will
be enrolled into indication-sepcific cohorts.